MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Phase 2
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Momotaro-Gene Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04013334
- Locations
- ๐บ๐ธ
Baylor College of Medicine, Houston, Texas, United States
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Momotaro-Gene Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01931046
- Locations
- ๐บ๐ธ
UCSD Moores Cancer Center, San Diego, California, United States
๐บ๐ธThe Methodist Hospital Research Institute, Houston, Texas, United States
๐บ๐ธBrigham and Women's Hospital, Boston, Massachusetts, United States
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
Phase 1
Withdrawn
- Conditions
- Prostate Cancer
- Interventions
- Biological: Ad-REIC/Dkk-3
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Momotaro-Gene Inc.
- Registration Number
- NCT01197209
- Locations
- ๐บ๐ธ
Mount Sinai School of Medicine, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath